What happens to side effects when you stop Wegovy

What the trial data show about stopping semaglutide

The most rigorous evidence comes from the STEP 1 extension, in which participants who had completed 68 weeks of semaglutide 2.4mg then stopped treatment and were followed for a further year without the medicine. On average, they regained roughly two-thirds of the weight they had lost, and many of the metabolic improvements (blood pressure, blood sugar, cholesterol) moved back toward their pre-treatment levels. That figure is worth sitting with: it isn't a sign that the medicine failed; it reflects how GLP-1 hormones normally work. Semaglutide substitutes for a hormonal signal that the body stops producing in sufficient quantity once the drug is absent. Take away the signal and the old appetite set-point reasserts itself. The NHS semaglutide page describes this mechanism in plain language and is worth reading before making any decision to stop. The STEP 1 results were published in the New England Journal of Medicine and are the evidence base behind NICE's recommendation that Wegovy be used for a maximum of two years within a specialist service.

None of this means stopping is always wrong. Some people reach a stable weight and choose to discontinue with their prescriber's support. Others stop because of side effects, a planned pregnancy, or surgery. The point is that stopping should be a planned clinical conversation, not an impulse.

Side effects that ease after your last injection

Semaglutide has a half-life of roughly seven days, which means it takes several weeks to clear your system fully. Most people find that the GI symptoms tied to active dosing (nausea, loose stools, burping, reflux) begin to settle within the first week after stopping and are largely gone by two weeks. If you were mid-titration and experiencing nausea after a recent dose increase, that particular wave will pass sooner than you might expect once the next dose doesn't arrive. How long these symptoms persist varies by dose and individual sensitivity, but the trend is consistent: GI effects are tied to active drug levels and fade as those levels fall. Injection-site reactions, if you had them, resolve quickly too. Fatigue and headache (occasionally reported during dose escalation) typically clear within the same window. Keep the used pens out of the fridge once you've finished, but make sure any unused pens stored in the fridge door are accounted for and returned or disposed of safely via your pharmacy.

The one side effect that doesn't ease is the effect on appetite. That returns. For most people it returns noticeably, often within the first two to four weeks. Nausea specifically after stopping is uncommon (the medicine suppresses nausea pathways rather than triggering them at baseline) so if you develop new nausea after discontinuing, that warrants a clinical conversation rather than a wait-and-see approach. Some people also notice changes in bowel habits, including diarrhea, in the days after their last injection, which typically settles as drug levels fall but should be monitored if it persists. If you are unsure how long nausea after stopping Wegovy is likely to continue for you, the answer depends on factors including your final dose and individual gut sensitivity, and is worth discussing with your prescriber if symptoms linger beyond a fortnight.

When to get medical help after stopping Wegovy

Stopping a GLP-1 medicine is not usually a medical emergency, but certain symptoms at any point during or after treatment require prompt attention. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but serious risk associated with GLP-1 medicines: severe stomach pain that builds rather than passes, particularly if it radiates toward the back or is accompanied by vomiting, needs same-day urgent assessment, call 111 or attend A&E depending on severity. Do not wait for a GP appointment. This risk exists during active treatment; it is less established as a post-stopping phenomenon, but the symptom pattern is the same and should be treated the same way.

Other reasons to seek prompt advice: symptoms of gallbladder problems (upper-right abdominal pain, jaundice), signs of severe dehydration from lingering GI illness, or any allergic reaction that wasn't present during treatment. If you stopped Wegovy abruptly before discussing it with your prescriber and you're now experiencing unexpected symptoms, a broader overview of stopping-related effects may help you work out what needs clinical input and what will resolve on its own. You can also report anything unusual to the MHRA's Yellow Card scheme, that includes post-treatment effects, and those reports genuinely inform ongoing safety monitoring for medicines like Wegovy.

Planning to stop: what a prescriber considers

If you're thinking about stopping Wegovy, the most useful conversation to have is with your prescriber before your next dose rather than after. Wegovy is licensed for weight management alongside diet and activity changes, and the clinical guidance from NICE (TA875) recommends reviewing progress at six months: if you haven't reached at least 5% weight loss on the maintenance dose by that point, continuing may not be appropriate. Equally, if you have responded well and want to know whether you can maintain without the medicine, that's a legitimate question with a structured answer, gradual tapering, lifestyle support, and monitoring for weight regain are all part of a responsible discontinuation plan.

A prescriber will also consider any medicines you take alongside Wegovy. Semaglutide slows gastric emptying, which can affect how some oral medicines are absorbed during treatment; once that slowing resolves after stopping, the absorption of those medicines returns to baseline, which may require adjustment. That's a practical reason to let your clinical team know you've stopped, even if you feel fine. Our prescribers discuss stopping as openly as they discuss starting, if you'd like that conversation as part of a consultation, you can explore the options on our treatment page.